Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in A sian patients with diabetes: The R egistry for A ssessing OAD U sage in D iabetes M anagement ( REASON ) A sia study (在亚洲糖尿病患者中评估基线特征、血糖控制情况以及口服降糖药物使用情况：使用登记表评估糖尿病治疗中口服药使用情况（REASON）的亚洲研究)

Background To assess baseline characteristics, glycemic control, and treatment with oral antidiabetic drugs ( OAD ) in type 2 diabetes mellitus ( T2DM ) patients. Methods This multinational, observational study recruited patients ≥21 years of age who were newly diagnosed and/or treated with OAD monotherapy for <6 months but were inadequately controlled. In cross‐sectional phase, data on demographics, medical history, diabetic complications and comorbidities, OAD treatment, glycosylated hemoglobin ( HbA1c ), and fasting blood glucose ( FBG ) were collected. In longitudinal phase evaluating 6‐month follow‐up of sulfonylurea ( SU )‐treated patients, additional data on reasons for not achieving HbA1c targets were collected. Results Of 1487 patients (mean [±SD] age 52.0 ± 11.6 years; 46.7% men; mean BMI 25.8 ± 4.4 kg/m 2 ) recruited, 75.9% were newly diagnosed, 73.3% had central obesity, 43.8% had hypertension, and 60.5% had dyslipidemia. The mean HbA1c was 9.8 ± 2.4%, and the mean FBG was 11.3 ± 4.3 mmol/ L . At T 0 (baseline) and T 6 (month 6 visit), 99.8% ( n  = 1066) and 97.1% ( n  = 830) patients received SU , respectively. There was decrease from T 0 to T 6 in mean HbA1c (10.2% vs 7.3%, respectively; P  < 0.0001) and mean FBG (12.0 vs 7.6 mmol/ L , respectively; P  < 0.0001). Number of patients with HbA1c <7% increased from T 0 (4.5%) to T 6 (46.8%). Reasons for not achieving target HbA1c included poor diabetes education (50.7%), non‐compliance to OADs (21.4%), and fear of hypoglycemia (19.7%). Conclusion Marked reductions in HbA1c and FBG are achievable in T2DM patients managed with OADs . However, patient education and compliance are important for achieving and maintaining treatment targets.